Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Malaria Vaccine Offers New Mode of Protection Against Disease

Published: Friday, November 29, 2013
Last Updated: Friday, November 29, 2013
Bookmark and Share
A novel malaria vaccine developed at Oxford University has shown promising results in the first clinical trial.

The trial was carried out in Oxford by researchers led by Professor Adrian Hill of the Jenner Institute at Oxford University, along with colleagues from the biotechnology company Okairos.

Some of the adult volunteers were completely protected against malaria in this initial study of the vaccine's efficacy.

It's the first time that a vaccine has been shown to have a protective effect through a sufficiently high immune response involving cells called CD8 T cells.

It is CD8 immune cells that are seen to mount a protective response against malaria in similar studies in mice.

Every existing vaccine in use – bar one – generates antibodies. But there are two arms to the body's immune system for fighting infection: antibodies and T cells. And this vaccine aims to stimulate an immune response involving T cells.

CD8 T cells are important because they are the primary killer cells in the immune system. They can attack nearly all types of infected cells – in this case liver cells infected with the malaria parasite. But this first demonstration of a large CD8 response from a vaccine could be relevant for tackling other diseases too.

'The vaccine was found to work by inducing CD8+ T cells that target the malaria parasite in the liver,' explains Professor Hill.

'For years a wide range of technologies have been assessed trying to induce protection through the cellular arm of the immune system with CD8+ T cells. But this is the first time that this has been achieved for any vaccine type against any disease.'

The Phase IIa trial in Oxford involved 36 people in total, of which 14 healthy adults received two different virus-based vaccines with the same malaria antigen eight weeks apart.

Of those 14, three people were protected from the bites of malaria-infected mosquitoes. A further five had delayed onset of malaria, demonstrating that over 90% of the malaria parasites had been killed by the vaccine-induced immune response.

Importantly, the size of the CD8 T cell response in these volunteers correlated with the degree of protection from malaria, suggesting that a sufficiently high cellular immune response is protective.

Ten further volunteers received only one of the vaccines and there were 12 controls. None of these people saw any protection against malaria from mosquito bites on the arm. All volunteers were closely monitored for malaria symptoms throughout, and those getting the disease were treated rapidly with drugs.

The trial results are published in the journal Nature Communications. The study was funded by the Medical Research Council with support from the National Institute for Health Research and the Wellcome Trust.

The results of larger Phase IIb trials of the efficacy of the vaccine in Africa are expected in 2014. They will determine more about the efficacy of this malaria vaccine where it is needed most.

If results continue to be positive, Professor Hill thinks that the best protection against malaria may come from combining the Oxford-developed vaccine with another that targets the sporozoite stage of the malaria parasite's life cycle. One such vaccine developed by GSK is in late-stage clinical trials.

The GSK vaccine called RTS,S works by stimulating antibodies against the malaria parasites before they enter the liver. Those that reach the liver would be mopped up by T cells stimulated by the Oxford vaccine.

Professor Hill and colleagues are currently carrying out a study in the UK to test how the GSK and Oxford vaccines might work together.

Malaria kills more than 660,000 people each year, most of whom are children in Africa.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Vaccine for Common Childhood Infection May Finally be Possible
Oxford University researchers have successfully completed the first human trial of a vaccine for RSV, a virus that is particularly dangerous to infants.
Friday, August 14, 2015
Researchers Discover Immune System’s 'Trojan Horse'
Oxford University researchers have found that human cells use viruses as Trojan horses, transporting a messenger that encourages the immune system to fight the very virus that carries it.
Monday, August 03, 2015
How do Networks Shape the Spread of Disease and Gossip?
A team of mathematicians from Oxford University, University of North Carolina at Chapel Hill, and Rutgers University used a set of mathematical rules to encode how a contagion spreads, and then studied the outcomes of these rules.
Thursday, July 23, 2015
A Combination Of Genes Results In Malaria Drug Resistance
The largest genome-wide study of the malaria parasite finds that the drug resistance occurs because of a key mutation happening on top of 'background' mutations which make the parasite more likely to develop drug resistance later.
Tuesday, January 20, 2015
Metal Test Could Help Diagnose Breast Cancer Early
It may be possible to develop a simple blood test that, by detecting changes in the zinc in our bodies, could help to diagnose breast cancer early.
Thursday, December 11, 2014
Booster Ebola Vaccine Enters First Trials
Trials aim to determine the safety of a candidate booster vaccine.
Thursday, December 04, 2014
Gene Therapy Trial Shows Promise for Type of Blindness
Patients showed improvements in their vision in dim light and two of the six were able to read more lines on the eye chart.
Thursday, January 16, 2014
Neanderthal Viruses Found in Modern Humans
Ancient viruses from Neanderthals have been found in modern human DNA by researchers at Oxford University and Plymouth University.
Tuesday, November 19, 2013
Global Warming Continues; Most Extreme Projections ‘Less Likely’
Observations of the climate system’s response to rising greenhouse gas levels are consistent with conventional estimates of the long-term ‘climate sensitivity’, despite a “warming pause” over the past decade.
Monday, May 20, 2013
Oxford Uni Announces Shell Support for Energy Research
Oxford University has announced that Shell International Exploration and Production B.V. has contributed a £5.9m boost to research into natural energy resources.
Thursday, May 09, 2013
Launch of £90m Initiative in Big Data and Drug Discovery at Oxford University
'Big data' to revolutionise healthcare.
Tuesday, May 07, 2013
New Stem Cell Approach for Blindness Successful in Mice
Researchers transplant developing cells into mice eyes and re-form the entire light-sensitive layer of the retina.
Tuesday, January 08, 2013
Novel Additive Boosts Effect of HIV and Flu Vaccines in Mice
Oxford scientists have discovered an 'adjuvant' which is added to a vaccine to enhance the immune response.
Wednesday, September 12, 2012
Protein Switch Controls How Stem Cells Turn Into New Heart Tissue
The scientists identified a protein called Fgf as the controlling factor which determines whether developing heart cells become heart muscle or blood vessels.
Tuesday, July 26, 2011
New Gene Discovered in Human Stem Cells may Benefit Transplant Patients
Oxford scientists have uncovered that the gene Nephroblastoma Overexpressed plays a key role in regulating the production of blood from stem cells.
Tuesday, May 01, 2007
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!